Mar 21 2020

BUSINESS DEVELOPMENT, Sun Pharmaceutical Industries Ltd, pharmaceutical business.

#Pharmaceutical #business


With global revenues of US$ 4.5 billion, Sun Pharma is the fourth largest specialty generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide. Sun Pharma is also India’s largest and most trusted pharmaceutical company. Our global presence is supported by more than 40 manufacturing facilities across 5 continents.

In the US market, which contributes a significant share of our revenues, we are the leader in the generic dermatology segment. We have strong capabilities in developing generic and complex products with a robust pipeline of 151 ANDAs. We have an established presence in Europe and key high-growth emerging markets like Russia, Romania, South Africa, Brazil and Mexico.

We are in constant search of partners that match our values, work ethics and commitment to patients. We regard partnership and collaboration as an integral part of our business strategy. This important initiative is supported by a dedicated team for global business development, licensing and post-alliance management.

Our track-record of successful collaborations includes in/out licensing of products and technologies, joint ventures, as well as mergers acquisitions. We offer a full range of both global and local integrated, organisational and commercial capabilities, combined with a track record of successful product launches. The financial strength of our company ensures appropriate investments in products.


We constantly seek to strengthen our presence, with a range of generic and speciality products, in Russia and CIS countries, China and South East Asia, Africa, Brazil, Mexico and other markets across the world.

We are currently interested in in-licensing products that are already marketed or are in late stage clinical development in our key therapy areas. We seek products that leverage our core strengths and complement our existing product portfolio in the following therapies:

  • CNS disorders
  • Cardiology
  • Diabetes and Metabolic disorders
  • Gastroenterology
  • Ophthalmology
  • Oncology
  • Pain
  • Allergy, Asthma and Inflammation
  • Gynaecology

We also have a strategic interest in in-licensing biosimilar products and new products based on recombinant/humanised monoclonal antibody technology used in these therapy areas.

We seek to establish a long term, mutually rewarding relationship based on the business model of exclusive marketing rights for the aforementioned geographies, as well as for co-marketing or strategic alliances for co-development of products, including clinical trials for necessary regulatory approvals.


We possess the requisite expertise and experience to develop complex generic products which are bioequivalent, sustained release oral dosage forms and long acting injectable depot formulations.

Our out-licensing product range includes dosage forms for oral, injectable, topical and transdermal routes developed through non-infringing routes and/or patented routes.

Our Organic synthesis team develops highly complex bulk actives like Peptides, Hormones, Steroids, Anticancer drugs and Cephalosporins through non-infringing routes and/or patented routes. We offer over 300 API products manufactured at US FDA/UK MHRA approved sites.

We seek out-licensing opportunities for our speciality generics, super generics, and bulk drugs for global markets in the following therapeutic areas:

Written by admin